Table 1.

Clinical parameters and their association with the risk score in the Tianjin cohort.

Clinical parameters		N (%)	PTTG1		p-value	SLC2A1		p-value	FAM83A		p-value	Risk score		p-value
			Low	High		Low	High		Low	High		Low	High
Age (years)
	<65	132 (73.3)	58	74	0.305	59	73	0.892	95	37	0.673	71	61	0.345
	≥65	48 (26.7)	17	31		22	26		33	15		22	26
Gender
	Males	79 (43.9)	33	46	0.980	30	49	0.094	49	30	0.017*	35	44	0.080
	Females	101 (56.1)	42	59		51	50		79	22		58	43
Clinical stage
	I	98 (54.4)	45	53	0.128	59	39	<0.0001***	82	16	<0.0001***	65	33	<0.0001***
	II	24 (13.3)	12	12		8	16		14	10		9	15
	III	58 (32.3)	18	40		14	44		32	26		19	39
T classification
	T1	95 (52.8)	43	52	0.632	57	38	<0.0001***	74	21	0.118	60	35	0.001***
	T2	63 (35.0)	24	39		20	43		38	25		28	35
	T3	16 (8.9)	5	11		2	14		12	4		2	14
	T4	6 (3.3)	3	3		2	4		4	2		3	3
N classification
	N0	113 (62.8)	51	62	0.227	63	50	0.001***	92	21	<0.0001***	68	45	0.003**
	N1	14 (7.8)	7	7		5	9		9	5		8	6
	N2	53 (29.4)	17	36		13	40		27	26		17	36
Smoke
	No smoking	114 (63.3)	49	65	0.638	61	53	0.003**	93	21	<0.0001***	65	49	0.059
	Smoking	66 (36.7)	26	40		20	46		35	31		28	38

*p < 0.05, **p < 0.01, and ***p < 0.001.

Bold values indicate statistical significance p < 0.05.